Phone: 86-17339854922
Mail: sales20@interlgroup.com
Add: Room 305 , 3/F , Haipai Decoration Office Building , Yudu Avenue , Yuncheng , Shanxi
lenvatinib Mesylate powder Raw Materials CAS 857890-39-2
Product Overview:
lenvatinib Mesylate powder is the Mesylate of Lovatinib, a multi-target tyrosine kinase inhibitor developed by Eisai, Inc. lenvatinib Mesylate CAS 857890-39-2 has a novel binding mode. In addition to inhibiting tyrosine kinases associated with other pro-angiogenic and carcinogenic signaling pathways involved in tumor proliferation, lenvatinib Mesylate Raw Materials selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors
lenvatinib Mesylate powder Raw Materials CAS 857890-39-2 Attributes
MF:C22H23ClN4O7S
MW:522.95862
EINECS:812-398-0
Specification:lenvatinib Mesylate powder
Sample:lenvatinib Mesylate powder
Brand:lenvatinib Mesylate powder
Appearance: powder
Storage: Cool Dry Place
Brand: chemical Raw Materials
Shelf Life: 2 Years
Test Method: HPLC
lenvatinib Mesylate powder Raw Materials CAS 857890-39-2 Details
Uses and synthesis of lenvatinib Mesylate powder
lenvatinib Mesylate powder is the Mesylate of Lovatinib, a multi-target tyrosine kinase inhibitor developed by Eisai, Inc. lenvatinib Mesylate CAS 857890-39-2 has a novel binding mode. In addition to inhibiting tyrosine kinases associated with other pro-angiogenic and carcinogenic signaling pathways involved in tumor proliferation, lenvatinib Mesylate Raw Materials selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptors
Applications/Functions of lenvatinib Mesylate powder
- lenvatinib Mesylate powder is a multi-target tyrosine kinase inhibitor that may work against a variety of cancers, so Eisai is also investigating levatinib for other cancers
- lenvatinib Mesylate CAS 857890-39-2 is superior to sorafenib, the current standard treatment for advanced hepatocellular carcinoma.
Physicochemical Property of lenvatinib Mesylate powder
